Project Grant R01AI203641
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $773,388 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to decode the cellular networks governing respiratory mucosal IgA immunity. The research addresses mechanisms driving robust respiratory mucosal immunity, particularly IgA responses following infection or vaccination, with the goal of informing next-generation mucosal vaccine strategies against...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded $444,125 to the University of Virginia on February 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to decode immune responses during sequential rhinovirus infections. The recipient will conduct a comprehensive analysis of immune cells and anti-viral mediators in blood and nasal specimens collected during sequential homotypic and heterotypic...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $795,313 on August 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on subcellular definition of accumulation in Escherichia coli as a strategy to address antimicrobial resistance. The research seeks to formulate foundational principles governing molecular characteristics that define cellular penetration in bacteria, similar to Lipinski's Rule of Five...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $161,450 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to fund a three-year research career development program supporting Dr. Lyndsey Muehling's training as a Research Assistant Professor. Dr. Muehling will complete a rigorous computational biology curriculum, engage in grant writing courses and career development activities, and receive mentorship from an...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $236,660 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate IL-33-dependent and IL-33-independent pathways in allergic asthma. The project examines how IL-33 signaling drives type-2 inflammatory responses in allergic asthma and why blockade of IL-33 has produced mixed clinical trial results despite its position as an upstream therapeutic target. The...
- The National Institute of Allergy and Infectious Diseases awarded the University of Missouri System $2.767 million on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the NFKB signaling network in the regulation of resident T cell memory. The research addresses how tissue-resident memory T cells (TRM) are generated and maintained in the lungs following infection. While CD8 TRM cells in multiple tissues provide superior protection against...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded the University of Virginia $253,445 on August 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate mechanistic insights into enteropathogen-mediated MUC3/4 signaling disruption and intestinal inflammation onset. The research uses human intestinal organoids to examine novel mechanisms triggering intestinal inflammation and mucosal...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $668,128 on August 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop artificial intelligence and machine learning methods for hospital-acquired infection risk prediction, surveillance, and infection control. The recipient will design a multi-disciplinary approach combining deep learning, agent-based modeling, human factors, and systems science to address gaps...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $242,250 on April 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate microbial drivers of oral vaccine failure in undernourished populations. The research addresses environmental enteric dysfunction, a subclinical intestinal malabsorption syndrome linked to growth stunting and undernutrition. Oral rotavirus vaccination shows significantly reduced efficacy in...
- The National Institute of Allergy and Infectious Diseases awarded The Trustees of Columbia University in the City of New York $3,144,408 on February 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate regulatory T cell memory in human tissues. The award funds research to characterize the role, identity, and function of human regulatory T cells (Tregs) across diverse tissues and their interactions with immune and structural cells. The project will...
The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $713,396 on August 21, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on the molecular mechanisms of protective lung resident memory T cells. The project examines how lung tissue-resident memory CD8+ T cells provide broad-spectrum protection against influenza infection, including heterologous protection against variant strains. The research focuses on a recently identified population of exhausted-like lung resident memory T cells (TRM-ELs) that differ transcriptionally and functionally from conventional resident memory T cells observed in other barrier tissues. Using genetic mouse models, multi-omics assays, and mucosal vaccination strategies, the research will define the transcriptional and epigenetic mechanisms maintaining these protective cells, identify molecular pathways driving their rapid protective responses during influenza reinfection, and evaluate immunization strategies to establish durable broad-spectrum protection, including against highly pathogenic avian influenza A(H5N1). Performance occurs in Charlottesville, Virginia. The period of performance extends through July 31, 2031. The assistance type is Project Grant.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $713.4k | 8/21/26 |